Metaphore Biotechnologies

Metaphore Biotechnologies is creating the next era of antibody medicines. The company’s platform integrates a proprietary experimental functional data engine with a mechanism-aware computational engine to design antibodies with new mechanisms to activate, tune and engage biology in entirely new ways. Metaphore’s pipeline is focused on high-value disease areas, including metabolic disease and immunology, where treatment requires complex approaches that go beyond blocking biology. The company was founded in 2021 in Flagship Labs, a unit of Flagship Pioneering.